Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of “Moderate Buy” from Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $29.20.

Several brokerages have commented on KURA. HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Wedbush restated an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research report on Friday, August 9th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th.

Institutional Investors Weigh In On Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna Fundamental Investments LLC acquired a new position in Kura Oncology in the 1st quarter valued at about $507,000. Hennion & Walsh Asset Management Inc. raised its stake in Kura Oncology by 42.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company’s stock valued at $3,875,000 after purchasing an additional 54,031 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares during the last quarter. Vanguard Group Inc. raised its stake in Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Finally, Sofinnova Investments Inc. raised its stake in Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares during the last quarter.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $17.37 on Wednesday. The firm’s fifty day moving average price is $19.45 and its 200 day moving average price is $20.15. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -8.00 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.53) earnings per share. On average, sell-side analysts expect that Kura Oncology will post -2.45 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.